Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: billy d who wrote (1666)	1/22/1999 6:05:00 PM
From: BMcV	Read Replies (2) \| Respond to of 10280

Robbie Stevens initiates coverage: biz.yahoo.com Friday January 22, 10:45 am Eastern Time Company Press Release SOURCE: BancBoston Robertson Stephens BancBoston Robertson Stephens Initiates Coverage of Sepracor, Inc., With a Long-Term Attractive Rating SAN FRANCISCO, Jan. 22 /PRNewswire/ -- The following is being issued by BancBoston Robertson Stephens, a member of the National Association of Securities Dealers, CRD number 41271: BancBoston Robertson Stephens senior emerging pharmaceutical analyst Donald B. Ellis today initiated coverage of Sepracor, Inc. (Nasdaq: SEPR - news) with a Long-Term Attractive rating. Sepracor, headquartered in Marlborough, Mass., is a specialty pharmaceutical company that develops improved chemical entity (ICE) versions of currently marketed and development-stage pharmaceuticals using its chiral chemistry and active metabolite technology. ''We are initiating coverage of Sepracor with a Long-Term Attractive ratings and a 12-month price target of $112,'' said Ellis. ''The company should represent a core holding in a growth healthcare portfolio and recommend building positions on weakness. ''Sepracor's prowess in chiral and metabolite chemistry has produced multiple meaningful partnerships within the major pharma industry. Sepracor has two approved drugs and six drugs in late phase clinical development, representing approximately $6.5 billion in annual sales,'' said Ellis. ''We believe Sepracor represents a favorable risk-reward opportunity, as billion dollar drugs are developed at minimal time and cost, compared with drug discovery,'' said Ellis. ''The company's technology has been well appreciated by the Street, with increases of 141 percent and 120 percent for 1997 and 1998, respectively. The technology offers significant advantages, including, increased potency and decreased toxicity, and may also provide new indications, in our opinion.'' Clients interested in receiving more information should contact their salesperson at 415-781-9700. BancBoston Robertson Stephens is a leading international investment banking firm focused on emerging growth companies. The firm's 55 senior research analysts cover over 575 companies. Additional information is available upon request.